FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Edge Pharma Cantharidin Gel-Forming Suspension Recall

Cantharidin Gel-Forming Suspension, 0

Edge Pharma, LLC · Colchester, VT

Risk level
Class II
Reported by FDA
Feb 2, 2022
Recall ID
D-0429-2022
Check your lot numberHow we source this data

Summary

Edge Pharma recalled Cantharidin Gel-Forming Suspension starting Dec 6, 2021. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0429-2022 on Feb 2, 2022. Reason: CGMP Deviations. Status: Terminated.

Why it was recalled

CGMP Deviations

Product description

Cantharidin Gel-Forming Suspension, 0.7%, 10 mL per vial, Multiple Dose Vial for Topical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05546 NDC 05446-0572-03

Lot numbers, UPCs & expiration codes

06-2021-11@6 12-08-2021, 07-2021-08@13 01-04-2022, 08-2021-06@6 02-02-2022, 08-2021-20@10 02-16-2022, 08-2021-26@6 02-22-2022, 08-2021-27@7 02-23-2022, 09-2021-02@5 03-01-2022, 09-2021-17@8 03-16-2022 & 09-2021-29@12 03-28-2022

Where it was sold

nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0429-2022
Classification
Class II
Status
Terminated
Recall initiated
Dec 6, 2021
FDA report date
Feb 2, 2022
Quantity
1173 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Edge Pharma, LLC

Original FDA data

Every field from FDA enforcement report D-0429-2022, exactly as published.

Show all FDA fields
City
Colchester
State
VT
Status
Terminated
Country
United States
Event ID
89172
Address
856 Hercules Dr
Code information
06-2021-11@6 12-08-2021, 07-2021-08@13 01-04-2022, 08-2021-06@6 02-02-2022, 08-2021-20@10 02-16-2022, 08-2021-26@6 02-22-2022, 08-2021-27@7 02-23-2022, 09-2021-02@5 03-01-2022, 09-2021-17@8 03-16-2022 & 09-2021-29@12 03-28-2022
Postal code
05446-8014
Report date
Feb 2, 2022
Product type
Drugs
Recall number
D-0429-2022
Classification
Class II
Recalling firm
Edge Pharma, LLC
Product quantity
1173 vials
Termination date
Jun 7, 2023
Reason for recall
CGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
Cantharidin Gel-Forming Suspension, 0.7%, 10 mL per vial, Multiple Dose Vial for Topical Use, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05546 NDC 05446-0572-03
Distribution pattern
nationwide
Recall initiation date
Dec 6, 2021
Initial firm notification
Press Release
Center classification date
Jan 24, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0429-2022, published Feb 2, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls